Alcami, a global pharmaceutical CDMO, has appointed Patrick D. Walsh as chairman and chief executive officer, effective immediately. He succeeds Walter J. Kaczmarek III, who is stepping down as chief executive.

Prior to joining Alcami, Mr. Walsh was co-founder and chief executive officer of TriPharm Services, a parenteral manufacturing business that was acquired by Alcami in January 2020. From 2015 to 2019, Mr. Walsh was the chief executive officer of Avista Pharma, a private equity-backed global provider of contract manufacturing, development, and analytical testing services. Mr. Walsh also served as chief executive officer of AAIPharma Services Corporation, a predecessor company to Alcami, from 2010 to 2014, leading the company through an impressive growth trajectory, culminating in the sale of the company. In addition to his duties at Alcami, Mr. Walsh currently serves as chairman of ANI Pharmaceuticals, a director at Landec Corporation, and a director at Industria Chemica Emiliano (I.C.E).
 
“Patrick’s impressive track record of driving growth and achieving high client satisfaction at leading pharmaceutical businesses makes him the ideal executive to lead Alcami forward,” said Jason Shideler, a managing director on Madison Dearborn Partners’ health care team and lead director at Alcami. “He brings a depth of industry knowledge and leadership experience that will support Alcami’s strategic efforts to continue to add scale in attractive growth markets and deliver high-quality services to the pharmaceutical industry.”